glp-1 drug market size Receptor Agonist & Analysis, 2026-2033 Market share of GLP-1 RAs
Description
Phase 3 clinical trial data showed average weight loss of 28.7% of body weight (approximately 71.2 pounds) at the 12 mg dose over 68 weeks
(2024, February 29)
There are also side effects to taking GLP-1s, most of which are related to gastrointestinal issues
It is a clinical one
Since then, GLP-1 RAs have attracted considerable academic interest, leading to the continuous introduction of innovative analogs into the pharmaceutical industry
doi: 10.1023/A:1018863716749 160 SchirraJHouckPWankUArnoldRGkeBKatschinskiM
